Hyperfine, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HYPR research report →
Range $1.4 – $2
Price Chart
About the company
Hyperfine, Inc. , a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
- CEO
- Maria Degois Sainz
- IPO
- 2021
- Employees
- 102
- HQ
- Guilford, CT, US
Get TickerSpark's AI analysis on HYPR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $49.73M
- P/E
- -1.80
- PEG
- -0.03
- P/S
- 2.61
- P/B
- 1.83
- EV/EBITDA
- -0.92
- Div Yield
- 0.00%
- Gross Margin
- 52.65%
- Op Margin
- -167.64%
- Net Margin
- -156.42%
- ROE
- -82.89%
- ROIC
- -67.00%
Latest fiscal year · YoY change
- Revenue
- $13.56M+5.2%
- Gross Profit
- $6.75M+14.6%
- Op Income
- $-37,085,000
- Net Income
- $-35,574,000+12.6%
- EPS
- $-0.43+23.2%
- OCF Growth
- +27.9%
- FCF Growth
- +25.6%
- 52W High
- $1.94
- 52W Low
- $0.49
- 50D MA
- $0.76
- 200D MA
- $1.09
- Beta
- 1.50
- RSI (14)
- 32
- Avg Volume
- 760.76K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Hyperfine posted its strongest quarter ever, with record revenue and gross margin, while showing improved operating leverage and reaffirming full-year guidance.· November 9, 2026
- Q3 revenue hit a record $6.0 million, up 53% sequentially and 73% year over year, with 14 units sold versus 8 a year ago.
- Gross margin reached a record 56.7%, up from 53.8% last year and 50.7% in Q2, marking the fifth straight quarter above 50%.
- Net cash burn fell to $5.6 million, down 29% sequentially, and quarterly revenue exceeded cash burn for the first time.
- Management said growth was broad-based across U.S. hospitals, U.S. offices, and international markets, with higher average selling prices supporting results.
- The company reaffirmed 2026 revenue and cash-burn guidance while raising the low end of gross margin guidance to 52.5% to 55%.
Hyperfine reported Q3 2026 revenue of $6.0 million, up from $3.4 million in Q3 2025, a 73% increase year over year and 53% sequentially. Gross profit was $3.4 million versus $1.8 million a year ago, and gross margin was 56.7% versus 53.8% in the prior-year period and 50.7% in Q2. Operating loss was $7.3 million, net loss was $6.0 million or $0.06 per share versus $11.0 million or $0.14 per share last year, and net cash burn was $5.6 million versus $5.9 million last year. For the first 9 months of 2026, revenue was $13.8 million, up 66% year over year, and 36 units were sold, up 64%. Full-year 2026 guidance was reaffirmed for revenue of $20 million to $22 million and net cash burn of $26 million to $28 million, while gross margin guidance was narrowed upward to 52.5% to 55%. The company ended the quarter with $37.9 million in cash and cash equivalents and said its cash runway remains into 2028, assuming no additional financing and no future debt draws.
Maria Sainz emphasized that Hyperfine is moving beyond a niche critical-care tool into a broader brain-health platform spanning hospitals, offices, international markets, and an emerging wellness opportunity. She highlighted three strategic tailwinds: the need for technologies with both clinical and economic ROI, the role of AI imaging in decentralizing care, and growth in wellness/prevention use cases. Her tone was upbeat and confident, but she framed the company’s next steps as execution-focused: driving Swoop adoption, converting health-system opportunities, submitting the contrast 510(k) by year-end, and scaling Model 2 internationally.
Brett Hale focused on operating leverage and cash discipline. He noted revenue rose 53% sequentially while operating expenses increased less than 2%, and said the quarter produced $1.4 million of additional gross profit versus only $0.2 million of extra operating expense. He cited record gross margin of 56.7%, operating loss of $7.3 million, net loss of $6.0 million, and net cash burn of $5.6 million, plus $37.9 million in cash at quarter-end. He also reaffirmed 2026 revenue guidance of $20 million to $22 million, net cash burn guidance of $26 million to $28 million, and said the debt facility still provides up to $25 million of additional capacity subject to loan terms.
Analysts focused on how fast health-system and IDN customers move from first placement to follow-on orders, and Maria said the process can take 2 to 3 quarters for larger systems because of procurement, legal, cybersecurity, and AI reviews. She said the common response is usually “not now,” not a rejection, because many customers are waiting for process completion or next-year capital budgets. Questions also centered on whether contrast approval changes adoption timing; management said it should help both hospital site-of-care expansion, especially the operating room, and office adoption by improving ROI and enabling use under CPT code 70553. Analysts pressed on the sustainability of the higher gross margin and whether spending will rise in 2027; management said only modest commercial investment is planned and that the current gross margin strength reflects both pricing and mix, not a one-time effect.
The bullish case from this call is that Hyperfine appears to be gaining real commercial traction across multiple channels at once: hospitals, offices, and international markets. Management pointed to recurring follow-on orders, a growing health-system funnel, improving unit volumes each quarter this year, and continued margin expansion with lower cash burn. The company also sees multiple upcoming catalysts, including the contrast 510(k), broader international rollout, and a potential wellness/longevity opportunity.
The main risks discussed are that enterprise hospital and IDN sales can be slow, with first placements often taking 2 to 3 quarters before follow-on orders materialize. Management also said some demand is dependent on capital-budget timing, which can push sales into future periods rather than the current quarter. In addition, the wellness/longevity opportunity is still early and management explicitly said it should not be expected to generate meaningful revenue in 2027, with more likely impact in 2028 and beyond.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 79.0%
- Shares Outstanding
- 90.99M
- Float Shares
- 71.91M
of shares held by institutions
85 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.66M | ▼ 16.45K |
| Vanguard Group Inc | 3.57M | ▲ 56.07K |
| Vanguard Capital Management LLC | 3.38M | 0 |
| Geode Capital Management, LLC | 1.95M | ▼ 13.35K |
| Fosun International Ltd | 1.74M | 0 |
| Catalio Capital Management, LP | 1.32M | 0 |
| State Street Corp | 1.03M | ▲ 16.40K |
| Alphabet Inc. | 898.72K | 0 |
| Renaissance Technologies LLC | 715.61K | ▼ 230.23K |
| Northern Trust Corp | 633.05K | ▲ 455.69K |
| Vanguard Fiduciary Trust Co | 630.62K | ▲ 63.51K |
| Vanguard Portfolio Management LLC | 547.50K | ▲ 302 |
Held by 77 ETFs
Biggest fund positions in HYPR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 24, 26 | TEISSEYRE THOMAS | sell | 7,345 |
| Aug 24, 26 | HALE BRETT | sell | 7,345 |
| Jun 3, 26 | Wolterman Dan | other | 52,600 |
| May 26, 26 | HALE BRETT | sell | 6,047 |
| May 26, 26 | TEISSEYRE THOMAS | sell | 6,047 |
| May 22, 26 | Fattori Ruth A | other | 157,700 |
| May 22, 26 | Wolterman Dan | other | 157,700 |
| May 22, 26 | Dahldorf John T | other | 157,700 |
| May 22, 26 | ROTHBERG JONATHAN M | other | 157,700 |
| Mar 31, 26 | HALE BRETT | other | 330,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HYPR coverage
Recent articles, reports, and earnings notes.
No research on HYPR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HYPR report →Hyperfine to Present at the Piper Sandler 38th Annual Healthcare Conference on December 3
businesswire.com · Nov 19
Hyperfine, Inc. (HYPR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
What Hyperfine (HYPR) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Hyperfine, Inc. Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 9
Sysmex (OTCMKTS:SSMXY) vs. Hyperfine (NASDAQ:HYPR) Critical Analysis
defenseworld.net · Nov 6
Hyperfine to Participate in Jefferies London and BTIG Tech-Enabled Healthcare Conferences
businesswire.com · Nov 3
Hyperfine Advances International Swoop System Model 2 Rollout and Highlights the Role of Portable MRI in Brain Health Awareness
businesswire.com · Oct 22
Hyperfine (NASDAQ: HYPR) revenue tops cash burn as it secures $40 million loan
defenseworld.net · Oct 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.